A guide to CAR T cell therapies: development, current status and future prospects

Area of Science:

• Immunology
• Biotechnology
• Oncology

Background:

• Chimeric antigen receptor (CAR) T cell therapy, approved in 2017, leverages T cell biology and synthetic immunoengineering.
• It has transformed B cell malignancy treatment, achieving durable remissions in leukemia, lymphoma, and multiple myeloma.

Purpose of the Study:

• To review foundational discoveries in CAR T cell therapy.
• To provide an overview of current CAR design principles, clinical development, and emerging strategies.
• To discuss enhancing efficacy, broadening indications, and achieving durable immune control.

Main Methods:

• Review of key discoveries in T cell biology and immunoengineering.
• Analysis of current CAR T cell therapy principles, clinical trials, and manufacturing innovations.
• Exploration of strategies for overcoming challenges like antigen heterogeneity and tumor microenvironment.

Main Results:

• CAR T cell therapy has shown significant success in B cell malignancies.
• Next-generation CAR designs are being developed for autoimmune diseases and solid tumors.
• Innovations in gene editing, manufacturing, and delivery are enhancing scalability, safety, and accessibility.

Conclusions:

• CAR T cell therapy is a powerful modality for cancer treatment with expanding applications.
• Ongoing innovations aim to improve efficacy, safety, and accessibility for broader disease control.
• Challenges remain in addressing tumor heterogeneity and ensuring long-term CAR T cell persistence.